- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03522870
Effects of Novel Flash Glucose Monitoring System on Glycemic Control in Adult Patients With Type 1 Diabetes Mellitus
February 8, 2023 updated by: Jianping Weng, Sun Yat-sen University
This trial is a randomized, multi-center, parallel-group, efficacy and safety study with a 26-weeks follow- up(after 2-week recruitment).
The study aims to: 1)compare the effects of novel flash glucose monitoring system (FGMS) and conventional Self Measurement of Blood Glucose (SMBG); and 2) optimize integrated management for glycaemic control in adult patients with type 1 diabetes who are sub-optimally controlled.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Subjects with Type 1 diabetes who meet criteria will be enrolled at up to eight clinical research sites in China.
Subjects will be randomized to either flash glucose monitoring system(Freestyle Libre®;Abbott Diabetes Care,Witney, Oxon,UK) or conventional Self Measurement of Blood Glucose (Bayer®)alone at least three times per day.
Primary outcome variable is the difference in HbA1c which will be analyzed in a central laboratory between baseline and the 26weeks follow-up.
Secondary outcome variables such as time-in-range, frequency and duration of and hyperglycemic episodes etc. will be assessed at baseline (Week 0 to 2), Week 12-14 and Week 24-26 via professional continuous glucose system (Ipro2®; Medtronic).
At the same time, demographic factors, clinical data, patient reported outcome (PROs) will be collected.
Assessment of Adverse Events will occur via self-reporting at each visit and/or phone call.
All patients will receive same ordinary diabetes education.
Study Type
Interventional
Enrollment (Actual)
104
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jianping Weng, PHD,MD
- Phone Number: 020-85253193
- Email: wengjp@vip.163.com
Study Contact Backup
- Name: Jinhua Yan, PHD,MD
- Phone Number: 020-85253193
- Email: yanjh79@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- The Third Affiliated Hospital of Sun Yat-sen University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 18 years and older;
- Diagnosed with type 1 diabetes with the criteria established by WHO in 1999,with duration more than 1 year;
- Glycosylated Hemoglobin A1c concentration between 7% and 10%;
- Self-monitor of blood glucose levels on a regular basis for 2 months previous( at least 3 times per day) and have willing to insist for at least 6 months
- Using CSII or MDI for at least 3 months, stable diabetes medication regimen for 3 months prior to study entry(change in insulin ≦20%).
- Willing to wear CGM;
- Able to speak, read, and write Chinese
Exclusion Criteria:
- Having used CGM 3 months prior to study entry;
- Had severe diabetic complications such as PDR in diabetic retinopathy and ESRD of diabetic nephropathy, assessed by investigators;
- Receiving oral steroid therapy for any disorders and continuous use of paracetamol.
- Had known allergy to medical-grade adhesives or CGM and its affiliated components;
- Being pregnant or planning pregnancy (as demonstrated by a positive test at study entry);
- Recent severe diseases like myocardial infarction,stroke,psychiatric diseases(historical/recent),malignant tumor, kidney disease(defined as eGFR<45), dermatosis, decided by investigator.
- Current participation in another investigational study (must have completed any previous studies at least 30 days prior to being enrolled in this study);
- Currently abusing illicit drugs, alcohol, or prescription drugs;
- Any condition that could impact reliability of the HbA1C measurement,(e.g.hemoglobinopathy, hemolytic anemia, chronic liver disease),decided by investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Flash Glucose Monitoring System
People selected to this group will using flash glucose monitoring system continuously on Week 2-14 and Week 14-26.
|
Using flash glucose monitoring system continuously on Week 2-14 and Week 14-26
Other Names:
|
ACTIVE_COMPARATOR: SMBG
People selected to this group will using SMBG continuously on Week 2-14 and Week 14-26.
|
Performing SMBG at least three times/day on Week 2-14 and Week 14-26
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycosylated Hemoglobin A1c
Time Frame: baseline,week14,week26
|
Difference in HbA1c at week 14 and week26 adjusted for baseline(week 0)
|
baseline,week14,week26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time in Range
Time Frame: baseline,week12-14,week24-26
|
Difference in time in Range (70-180 mg/dL) assessed in week 12-14 and week 24-26 adjusted for baseline(week 0 to 2)
|
baseline,week12-14,week24-26
|
Time in Hypoglycemia
Time Frame: baseline,week12-14,week24-26
|
Difference in time in hypoglycaemia (<70mg/dL,<54mg/dL and<40mg/dL) assessed in week 12-14 and week 24-26 adjusted for baseline(week 0 to 2)
|
baseline,week12-14,week24-26
|
Time in Hyperglycaemia
Time Frame: baseline,week12-14,week24-26
|
Difference in time in hyperglycaemia (>180mg/dL and>300mg/dL) assessed in week 12-14 and week 24-26 adjusted for baseline(week 0 to 2)
|
baseline,week12-14,week24-26
|
Percentage of HbA1c in Range
Time Frame: baseline,week14,week26
|
Difference in Percentage of HbA1c at week14 and week 26 adjusted for baseline(week 0)
|
baseline,week14,week26
|
Standard deviation of glucose
Time Frame: baseline,week12-14,week24-26
|
Difference in standard deviation of glucose assessed in week 12-14 and week 24-26 adjusted for baseline(week 0 to 2)
|
baseline,week12-14,week24-26
|
Mean glucose levels
Time Frame: baseline,week12-14,week24-26
|
Difference in mean glucose levels assessed in week 12-14 and week 24-26 adjusted for baseline(week0 to 2)
|
baseline,week12-14,week24-26
|
The area under the curve of hypoglycemia/ hyperglycaemia
Time Frame: baseline,week12-14,week24-26
|
baseline,week12-14,week24-26
|
|
Frequency in hypoglycemia/ hyperglycaemia
Time Frame: baseline,week12-14,week24-26
|
baseline,week12-14,week24-26
|
|
Frequency in severe hypoglycaemia
Time Frame: baseline,week12-14,week24-26
|
baseline,week12-14,week24-26
|
|
Frequency in adverse events about device
Time Frame: 26weeks
|
26weeks
|
|
Frequency in using FGM
Time Frame: 24 weeks
|
24 weeks
|
|
Frequency in SMBG
Time Frame: 26 weeks
|
26 weeks
|
|
Total daily dose of insulin
Time Frame: 26 weeks
|
26 weeks
|
|
The Diabetes Distress Scale (DDS)
Time Frame: baseline,week 14 and week 26
|
The Chinese version of the Diabetes Distress Scale is to evaluate diabetes-related emotional distress in Chinses diabetic patients.
The scale consists of 17 items, contains four domains including emotional burden sub-scale, physician-related distress subscale, regimen-related distress subscale, and diabetes-related interpersonal distress.
Each item is rated on a 6-point Likert scale from 1(no problem) to 6(serious problem).
An average score ≥3 is the cut-off point which is considered to more than moderate problem.
Administration time is approximately 10 minutes.
|
baseline,week 14 and week 26
|
Hypoglycaemia Fear Scale(HFS)
Time Frame: baseline,week 14 and week 26
|
The Chinses version of Hypoglycemia Fear Survey II- Worry Scale (CHFSII-WS) is to evaluate psychological status for diabetic patients.
Change in Hypoglycemia Fear Scale (HFS) score will be assessed in week 14 and week 26 adjusted for baseline(week0).
These validated surveys consist of 18 questions which measure dimensions of anxiety and fear surrounding hypoglycemia.
Each item is rated on 5-point Likert scale from 0(never related) to 4(very related).
"Never relative" scores 1, and so on and so forth, and "very related" scores 4. Patients with higher scores are considered with more anxieties and fear of hypoglycemia.
Administration time is approximately 10 minutes.
|
baseline,week 14 and week 26
|
EQ-5D-5L
Time Frame: baseline,week 14 and week 26
|
The Chinese version of the EQ-5D-5L is widely used to evaluate quality of life.
The EQ-5D-5L is converted to a single summary index by applying a formula that essentially attaches weights to each of the levels in each dimension.
The formula is based on the valuation of EQ-5D health states from general population samples.
It contains the health description system and Visual Analogue Score (VAS).
The health description system includes 5 dimensions including mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each item is rated on 5 levels from 1(no problems) to 5(extreme problem).
And the EQ-VAS is to evaluate the health condition assessed by patients.
The top score (100) means the best health conditions and the bottom one (0) means the worst.
Administration time is approximately 3minutes.
Difference in EQ-5D-5Ls assessed in week 14 and week26 adjusted for baseline(week0-2).
|
baseline,week 14 and week 26
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Xueying Zheng, MD, The First Affiliated Hospital of USTC
- Principal Investigator: Jing Lu, PHD, Department of Endocrinology, Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Zhou Y, Deng H, Liu H, Yang D, Xu W, Yao B, Yan J, Weng J. Effects of novel flash glucose monitoring system on glycaemic control in adult patients with type 1 diabetes mellitus: protocol of a multicentre randomised controlled trial. BMJ Open. 2020 Dec 4;10(12):e039400. doi: 10.1136/bmjopen-2020-039400.
- Liu H, Yang D, Deng H, Xu W, Lv J, Zhou Y, Luo S, Zheng X, Liang H, Yao B, Qiu L, Wang F, Liu F, Yan J, Weng J. Impacts of glycemic variability on the relationship between glucose management indicator from iPro2 and laboratory hemoglobin A1c in adult patients with type 1 diabetes mellitus. Ther Adv Endocrinol Metab. 2020 Jun 8;11:2042018820931664. doi: 10.1177/2042018820931664. eCollection 2020.
- Yan J, Zhou Y, Zheng X, Zheng M, Lu J, Luo S, Yang D, Deng H, Xu W, Bi Y, Bao W, Weng J. Effects of intermittently scanned continuous glucose monitoring in adult type 1 diabetes patients with suboptimal glycaemic control: A multi-centre randomized controlled trial. Diabetes Metab Res Rev. 2023 Jan 20:e3614. doi: 10.1002/dmrr.3614. Online ahead of print.
- Zhou Y, Mai X, Deng H, Yang D, Zheng M, Huang B, Xu L, Weng J, Xu W, Yan J. Discrepancies in glycemic metrics derived from different continuous glucose monitoring systems in adult patients with type 1 diabetes mellitus. J Diabetes. 2022 Jul;14(7):476-484. doi: 10.1111/1753-0407.13296. Epub 2022 Jul 21.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 1, 2018
Primary Completion (ACTUAL)
June 19, 2022
Study Completion (ACTUAL)
June 19, 2022
Study Registration Dates
First Submitted
April 18, 2018
First Submitted That Met QC Criteria
April 30, 2018
First Posted (ACTUAL)
May 11, 2018
Study Record Updates
Last Update Posted (ACTUAL)
February 10, 2023
Last Update Submitted That Met QC Criteria
February 8, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017YFC1309601
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Flash glucose monitoring system
-
RenJi HospitalUnknownCritical Illness | Systemic Lupus Erythematosus | Diabetic Blood Glucose MonitoringChina
-
Charles University, Czech RepublicUnknownDiabetes Mellitus, Type 1Czechia
-
Campus Bio-Medico UniversityRecruiting
-
Abbott Diabetes CareCompleted
-
Abbott Diabetes CareCompletedDiabetes MellitusUnited Kingdom, Germany, Ireland
-
Abbott Diabetes CareCompleted
-
Shanghai General Hospital, Shanghai Jiao Tong University...UnknownDiabetes Mellitus, Type 2 | Flash Glucose MonitoringChina
-
Abbott Diabetes CareCompleted
-
Jessa HospitalUnknownMetabolic Control | Flash Glucose MonitoringBelgium
-
Abbott Diabetes CareCompleted